These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1714748)

  • 21. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein.
    Martinon F; Gras-Masse H; Boutillon C; Chirat F; Deprez B; Guillet JG; Gomard E; Tartar A; Levy JP
    J Immunol; 1992 Nov; 149(10):3416-22. PubMed ID: 1385524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160.
    Wahren B; Bratt G; Persson C; Levén B; Hinkula J; Gilljam G; Nordlund S; Eriksson L; Volvovitz F; Broliden PA
    J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):220-9. PubMed ID: 7906300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.
    Orentas RJ; Hildreth JE; Obah E; Polydefkis M; Smith GE; Clements ML; Siliciano RF
    Science; 1990 Jun; 248(4960):1234-7. PubMed ID: 2190315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
    Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
    AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
    Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
    J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Berman PW; Gregory TJ; Riddle L; Nakamura GR; Champe MA; Porter JP; Wurm FM; Hershberg RD; Cobb EK; Eichberg JW
    Nature; 1990 Jun; 345(6276):622-5. PubMed ID: 2190095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity.
    Picard O; Achour A; Bernard J; Halbreich A; Bizzini B; Boyer V; Desgranges C; Bertho JM; Lachgar A; Polliotti B
    J Acquir Immune Defic Syndr (1988); 1992; 5(6):539-46. PubMed ID: 1588488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of human immunodeficiency virus-specific T cell responses in rhesus monkeys by synthetic peptides from gp160.
    Nehete PN; Satterfield WC; Matherne CM; Arlinghaus RB; Sastry KJ
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):235-40. PubMed ID: 8471313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. Dissection of the immune response.
    Akerblom L; Nara P; Dunlop N; Morein B
    AIDS Res Hum Retroviruses; 1991 Jul; 7(7):621-7. PubMed ID: 1768464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
    Pincus SH; Messer KG; Hu SL
    J Clin Invest; 1994 Jan; 93(1):140-6. PubMed ID: 8282780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-mediated immune proliferative responses to HIV-1 of chimpanzees vaccinated with different vaccinia recombinant viruses.
    Van Eendenburg JP; Yagello M; Girard M; Kieny MP; Lecocq JP; Muchmore E; Fultz PN; Riviere Y; Montagnier L; Gluckman JC
    AIDS Res Hum Retroviruses; 1989 Feb; 5(1):41-50. PubMed ID: 2470398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.
    Warren RQ; Wolf H; Shuler KR; Eichberg JW; Zajac RA; Boswell RN; Kanda P; Kennedy RC
    J Virol; 1990 Feb; 64(2):486-92. PubMed ID: 2404138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An endogenously synthesized decamer peptide efficiently primes cytotoxic T cells specific for the HIV-1 envelope glycoprotein.
    Bergmann C; Stohlmann SA; McMillan M
    Eur J Immunol; 1993 Nov; 23(11):2777-81. PubMed ID: 7693478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-CD4 antibodies generated in response to HIV-1 rgp160 immunization of HIV-1-infected chimpanzees.
    Keiser P; Fernie B; Tacket C; Wecksler W; Keay S
    AIDS; 1993 Jan; 7(1):136-8. PubMed ID: 8442909
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.
    Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.